Wellington Management Amends Alnylam Pharma Stake (12th Update)
Ticker: ALNY · Form: SC 13G/A · Filed: Feb 9, 2024 · CIK: 1178670
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, pharmaceuticals
TL;DR
**Wellington Management Group LLP is still a big holder of Alnylam stock, showing continued institutional interest.**
AI Summary
Wellington Management Group LLP, a major investment firm, filed an amendment (SC 13G/A) on February 9, 2024, updating its ownership in Alnylam Pharmaceuticals, Inc. as of December 29, 2023. This filing, Amendment No. 12, indicates that Wellington continues to hold a significant stake in Alnylam's Common Stock, signaling their ongoing confidence or strategic interest in the pharmaceutical company. For investors, this means a large institutional player is maintaining its position, which can be seen as a vote of confidence in Alnylam's future prospects.
Why It Matters
This filing shows that a major institutional investor, Wellington Management Group LLP, is still a significant shareholder in Alnylam Pharmaceuticals, Inc., which can influence market perception and investor confidence.
Risk Assessment
Risk Level: low — This filing is an update on an existing institutional holding, not a new position or a significant divestment, indicating stability.
Analyst Insight
Investors should note that a major institutional investor, Wellington Management Group LLP, is maintaining its position in Alnylam Pharmaceuticals, Inc. This suggests continued confidence in the company, but further analysis of Wellington's specific share count (not provided in this excerpt) would be needed to gauge the exact level of commitment.
Key Players & Entities
- Wellington Management Group LLP (company) — the reporting person and institutional investor
- Alnylam Pharmaceuticals, Inc. (company) — the subject company whose securities are being reported
- December 29, 2023 (date) — the date of the event requiring the filing
- February 9, 2024 (date) — the filing date of the SC 13G/A
- 02043Q107 (other) — CUSIP Number for Alnylam Pharmaceuticals, Inc. Common Stock
Forward-Looking Statements
- Wellington Management Group LLP will maintain a significant stake in Alnylam Pharmaceuticals, Inc. (Wellington Management Group LLP) — medium confidence, target: next 12 months
FAQ
What type of filing is this document?
This document is an SC 13G/A, which is an amendment to a Schedule 13G filing, specifically Amendment No. 12, as stated in the filing.
Who is the reporting person in this filing?
The reporting person is Wellington Management Group LLP, as clearly identified in the 'NAMES OF REPORTING PERSONS' section.
What is the name of the issuer whose securities are being reported?
The name of the issuer is Alnylam Pharmaceuticals, Inc., as stated under 'Name of Issuer' on the cover page.
What was the 'Date of Event Which Requires Filing of this Statement'?
The 'Date of Event Which Requires Filing of this Statement' was December 29, 2023, according to the cover page of the filing.
What is the CUSIP number for the class of securities reported?
The CUSIP number for the Common Stock of Alnylam Pharmaceuticals, Inc. is 02043Q107, as listed on the cover page and in the CUSIP No. field.
Filing Stats: 1,968 words · 8 min read · ~7 pages · Grade level 9.8 · Accepted 2024-02-09 08:40:49
Filing Documents
- SEC13G_Filing.htm (SC 13G/A) — 35KB
- 0000902219-24-000264.txt ( ) — 37KB
From the Filing
SC 13G/A 1 SEC13G_Filing.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 12 ) * Alnylam Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 02043Q107 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act, but shall be subject to all other provisions of the Act (however, see the Notes.) CUSIP No. 02043Q107 1. NAMES OF REPORTING PERSONS Wellington Management Group LLP 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ] (b) [ ] 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION Massachusetts NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER 0 6. SHARED VOTING POWER 7,095,212 7. SOLE DISPOSITIVE POWER 0 8. SHARED DISPOSITIVE POWER 7,252,907 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 7,252,907 10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES [ ] 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 5.78% 12. TYPE OF REPORTING PERSON HC CUSIP No. 02043Q107 1. NAMES OF REPORTING PERSONS Wellington Group Holdings LLP 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ] (b) [ ] 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION Delaware NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER 0 6. SHARED VOTING POWER 7,095,212 7. SOLE DISPOSITIVE POWER 0 8. SHARED DISPOSITIVE POWER 7,252,907 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 7,252,907 10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES [ ] 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 5.78% 12. TYPE OF REPORTING PERSON HC CUSIP No. 02043Q107 1. NAMES OF REPORTING PERSONS Wellington Investment Advisors Holdings LLP 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ] (b) [ ] 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION Delaware NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER 0 6. SHARED VOTING POWER 7,095,212 7. SOLE DISPOSITIVE POWER 0 8. SHARED DISPOSITIVE POWER 7,252,907 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 7,252,907 10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES [ ] 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 5.78% 12. TYPE OF REPORTING PERSON HC CUSIP No. 02043Q107 1. NAMES OF REPORTING PERSONS Wellington Management Company LLP 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ] (b) [ ] 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION Delaware NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER 0 6. SHARED VOTING POWER 7,021,133 7. SOLE DISPOSITIVE POWER 0 8. SHARED DISPOSITIVE POWER 7,055,912 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 7,055,912 10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES [ ] 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 5.62% 12. TYPE OF REPORTING PERSON IA Item 1. (a) Name of Issuer Alnylam Pharmaceuticals, Inc. (b) Address of Issuer's Principal Executive Offices 675 West Kendall Street Henri A. Termeer Square Cambridge, MA 02142 Item 2. (a) Name of Person Filing Wellington Management Group LLP Wellington Group Holdings LLP Wellington Investment Advisors Holdings LLP Wellington Management Company LLP (b) Address of Principal Business Office or, if None, Residence c/o Wellington Management Company LLP 280 Congress Street Boston, MA 02210 (c) Citizenship Wellington Management Group LLP - Massachusetts Wellington Group Holdings LLP - Delaware Wellington Investment Advisors Holdings LLP - Delaware Wellington Management Company LLP - Delaware (d) Title of Class of Securities Common Stock (e) CUSIP Number 02043Q107 Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a: (a) [ ] Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o). (b) [ ] Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c). (c)